Best tumor response in cycle 1 per independent radiologic assessment
| Patient response rate . | Cohorts I + III . | Cohort II . | Total . |
|---|---|---|---|
| Evaluable patients, n* | 20 | 1 | 21 |
| Overall response rate, n (%)† | 8 (40.0) | 1 (100.0) | 9 (42.9) |
| Best overall response, n (%) | |||
| CR | 4 (20.0) | 0 (0.0) | 4 (19.0) |
| PR | 4 (20.0) | 1 (100.0) | 5 (23.8) |
| Stable disease | 2 (10.0) | 0 (0.0) | 2 (9.5) |
| Progressive disease | 10 (50.0) | 0 (0.0) | 10 (47.6) |
| All patients, n | 23 | 2 | 25 |
| Overall response rate, n (%)† | 8 (34.8) | 1 (50.0) | 9 (36.0) |
| Best overall response, n (%) | |||
| CR | 4 (17.4) | 0 (0.0) | 4 (16.0) |
| PR | 4 (17.4) | 1 (50.0) | 5 (20.0) |
| Stable disease | 3 (13.0) | 0 (0.0) | 3 (12.0) |
| Progressive disease | 10 (43.5) | 0 (0.0) | 10 (40.0) |
| No response assessment | 2 (8.7) | 1 (50.0) | 3 (12.0) |
| Patient response rate . | Cohorts I + III . | Cohort II . | Total . |
|---|---|---|---|
| Evaluable patients, n* | 20 | 1 | 21 |
| Overall response rate, n (%)† | 8 (40.0) | 1 (100.0) | 9 (42.9) |
| Best overall response, n (%) | |||
| CR | 4 (20.0) | 0 (0.0) | 4 (19.0) |
| PR | 4 (20.0) | 1 (100.0) | 5 (23.8) |
| Stable disease | 2 (10.0) | 0 (0.0) | 2 (9.5) |
| Progressive disease | 10 (50.0) | 0 (0.0) | 10 (47.6) |
| All patients, n | 23 | 2 | 25 |
| Overall response rate, n (%)† | 8 (34.8) | 1 (50.0) | 9 (36.0) |
| Best overall response, n (%) | |||
| CR | 4 (17.4) | 0 (0.0) | 4 (16.0) |
| PR | 4 (17.4) | 1 (50.0) | 5 (20.0) |
| Stable disease | 3 (13.0) | 0 (0.0) | 3 (12.0) |
| Progressive disease | 10 (43.5) | 0 (0.0) | 10 (40.0) |
| No response assessment | 2 (8.7) | 1 (50.0) | 3 (12.0) |